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Background: High circulating tumor cell (CTC) counts are associated with poor prognosis in advanced prostate
cancer, and recently CTC number was suggested to be a surrogate for survival in metastatic castrate-resistant
prostate cancer (mCRPC). Ki67 and vimentin are well-characterised markers of tumour cell proliferation and the
epithelial-mesenchymal transition (EMT), respectively. Here we asked if the expression of vimentin and Ki67 in
CTCs offered prognostic or predictive information in mCRPC.
Methods: In two separate patient cohorts, anti-vimentin or anti-Ki67 antibodies were added to the free channel in
the CellSearch® system for analysis of peripheral blood samples. For each cohort, association of CTC number with
clinical characteristics were assessed using Fisher’s exact, Mann-Whitney and chi-squared tests. Kaplan-Meier
method and log-rank tests were used to analyse overall survival (OS) of vimentin-expressing and Ki67-expressing
CTC patient cohorts.
Results: In this retrospective analysis, CTC vimentin expression was analysed in 142 blood samples from 93 patients,
and CTC Ki67 expression was analysed in 90 blood samples from 51 patients. In the vimentin cohort, 80/93 (86 %)
of baseline samples from patients were CTC-positive overall (≥1 total CTC per 7.5 mls blood), and 30/93 (32.3 %)
vimentin CTC-positive (≥1 vimentin-positive CTC per 7.5 mls blood). 41/51 (80.4 %) of baseline samples from
patients in the Ki67 cohort were CTC-positive overall, and 23/51 (45.1 %) Ki67 CTC-positive (≥1 Ki67-positive CTC
per 7.5 mls blood). There was no significant difference in baseline PSA in patients with vimentin-positive CTC at
baseline versus those with no vimentin-positive CTC at baseline (p = 0.33). A significant reduction in OS was shown
in patients with vimentin-positive CTC compared to those without vimentin-positive CTC (median 305 days vs
453 days, p = 0.0293). There was no significant difference in baseline PSA in patients with Ki67-positive CTC at
baseline versus those without Ki67-positive CTC (p = 0.228), but OS was significantly reduced in the Ki67-positive
CTC group (median 512 days vs 751 days, p = 0.0091). No changes in relative proportion of vimentin- or Ki67-
positive CTCs were observed in post-treatment samples compared to baseline.
Conclusions: Analysis of vimentin and Ki67 expression can straightforwardly be assessed in CTCs from patients with
mCRPC. Poorer survival outcomes were observed in vimentin- and Ki67-positive CTC patients.
Translational study protocols: CEC-CTC (IDRCB2008-AOO585-50) and Petrus (NCT01786031).
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Circulating tumor cells (CTCs), captured as a ‘liquid biopsy’
from blood for enumeration and biological characterization
of cancers, have the potential to replace biopsy and provide
important clinical information on prognosis, therapeutic
choice, and drug resistance, while also being of interest for
drug development and biomarker discovery. They may
represent an alternative source of tumor tissue which
is easily accessible using a simple blood test, allowing
longitudinal monitoring of tumor aggression and biology
at different timepoints to guide therapeutic decisions in a
patient’s treatment course [1–3]. Prostate cancer was one
of the first malignancies where the prognostic value of
monitoring CTC numbers was demonstrated in patients
with advanced disease, both before and during treatment
for castrate-resistant prostate cancer (CRPC) using the
FDA-approved CellSearch technology [4, 5]. Moreover,
a recent prospective trial demonstrated that CTC
count and LDH value could be a surrogate of overall
survival in a population of mCRPC patients treated
with abiraterone in the COU-301 trial [6]. The potential
of CTC for molecular characterization has been demon-
strated on a number of occasions, most recently in CRPC
with the demonstration of their variable androgen recep-
tor (AR) expression [7–12].
Ki-67 is a nuclear protein that is associated with ribo-
somal RNA synthesis and may be necessary for cell cycle
proliferation. Its tissue staining has consistently demon-
strated prognostic value in prostate cancer, and has been
tested in men managed with radiation and surgery, as
well as in those conservatively managed without defini-
tive therapy [13–16]. One group of studies used
pretreatment biopsies of patients undergoing radiation
and androgen deprivation as part of the Radiation Therapy
Oncology Group (RTOG) 92–02 trial, defining a cut-off of
11.3 % high Ki-67 staining as independently correlated with
an increase risk in distant metastasis, cancer-specific death,
and overall death [13, 14]. A Mayo clinic study described
similar outcomes from patient tissue taken before or dur-
ing definitive prostatectomy, using a staining threshold of
6 % high Ki67 (present in 11 % of patients) which corre-
lated with increased risks of cancer progression and
cancer-specific mortality [16]. The phase III GETUG 12
study, which assessed androgen-deprivation therapy in
high risk localized prostate cancer, showed that high Ki67
predicted an unfavourable PFS using a median Ki67 cutoff
of 1 % [17]. Finally, 243 conservatively-treated patients
from the Transatlantic Prostate Group were shown to have
significantly increased risk of cancer-specific mortality in
the 5 % of patients who had >10 % Ki67 staining [15]. The
detection of Ki67 in CTCs has been previously reported
using a microfluidic CTC detection method, offering the
opportunity to assess if longitudinal quantification of
proliferative and non-proliferative subpopulations may bemore clinically informative than examination of total CTC
count and/or biopsy alone [18].
Vimentin is a filamental protein expressed in mesen-
chymal cells, often recorded as a marker of tumour cell
invasion via its expression during activation of the
epithelial-mesenchymal transition (EMT) [19, 20]. Com-
pared to Ki67, its use in biological interrogation of CTC
is more commonplace. Interest in EMT/vimentin in the
CTC field continues due to the continuing biological
challenge it represents: CTC undergo EMT in order to
enter the bloodstream where they are captured, yet
many current enrichment methods and definitions of
CTC do not incorporate mesenchymal markers such as
vimentin. It is hypothesized that, in cancers such as
non-small cell lung cancer which have a low yield of
CTC via EPCAM (epithelial)-antibody enrichment in
CellSearch, many ‘EMT’ and mesenchymal CTC are
missed as a consequence of sub-optimal enrichment
methods [21–24]. Despite this potential problem, the
validity of EMT analysis using the CellSearch platform
has previously been confirmed by a report documenting
the co-expression of vimentin with cytokeratin in sam-
ples from 10/10 CRPC patients, with 108/126 CTCs in
total co-expressing these markers [25].
Given the association of Ki67 and vimentin with poor
prognosis in metastatic CRPC biopsy, we hypothesized
that vimentin or Ki67 expression in CTC would offer a
poorer prognostic picture compared to that observed in
patients with no vimentin- or Ki67-positive CTCs. We
analysed Ki67 and vimentin expression in CTC derived
from a total of 144 advanced prostate cancer patients
using CellSearch technology, optimized and validated to
assay Ki67 and vimentin in separate patient cohorts. Our
results corroborate those seen in tumour biopsies, with
a diminished OS observed in patients with vimentin-
expressing CTCs and those with Ki67-expressing CTCs.
Methods
Patients
Peripheral blood (7.5 ml) was collected from meta-
static CRPC patients recruited to one of two Gustave-
Roussy CTC translational study protocols, CEC-CTC
(IDRCB2008-AOO585-50) and Petrus (NCT01786031).
For eligibility, patients had to have a confirmed diagnosis
of metastatic CRPC (either by contemporaneous or histor-
ical biopsy). All patients offered their written informed
consent and were enrolled on institutional protocols
approved by the local Gustave-Roussy ethics review com-
mittee. The following minimal clinical data were collected:
CTC count at baseline and following their first cycle of
treatment (at cycles 2–3), date of CTC sample, date of
progression or death (if applicable), histology, metastatic
sites, systemic treatment due at time of baseline CTC
sampling, and previous treatment. Routine laboratory
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at first blood sample after initiation of treatment, includ-
ing prostate-specific antigen (PSA) for response assess-
ment. Patients were recruited for the analysis between
December 2010 until November 2014.
CellSearch
Collection of blood and immunofluorescent (IF) staining
of CTC was performed using the CellSearch® system
(Janssen Diagnostics, LLC), as previously reported [4, 26].
Candidate cells (CTC +/− vimentin, or CTC +/− Ki67 –
all cytokeratin positive) were identified using the Cell-
Tracks Analyzer II (Janssen Diagnostics, LLC) according
to methods and IF expression criteria previously reported
[27]. The number of CTCs is presented per 7.5 ml of
blood. Unless otherwise stated in the text, patients in this
study were defined as Ki67- or vimentin-CTC positive if
they had ≥1 vimentin-positive or Ki67-positive CTCs. For
Additional file 1: Figure S3, two separate patient cohorts
were assessed in exploratory analyses: for (a) and (c),
patients with ≥5 total CTCs and ≥1 vimentin-positive or
Ki67-positive CTC were compared with those patients
with ≥5 total CTCs and no vimentin-positive or Ki67-
positive CTC; for (b) and (d), the 10 CTC-positive
patients with the highest proportions of vimentin/
Ki67-positive CTCs were compared with the 10 CTC-
positive patients with the lowest proportions of
vimentin/Ki67-positive CTCs.
Ki67 and vimentin validation
This was established using the CellSearch platform: in
separate experiments, FITC- labelled anti-vimentin
antibody (Santa-Cruz, ’vimentin cohort’) and anti-Ki67
antibody (BD Biosciences, ’Ki67 cohort’) were added
to the free channel in the CellSearch system. Anti-
vimentin was tested using donor blood spiked with
A549 (vimentin + ve) and T47D (vimentin -ve) cancer
cell lines (Additional file 1: Figure S1a). Anti-Ki67
was tested in donor blood spiked with A549 and
SKBR3 cancer cell lines: in these cell lines, phyto-
haemagglutinin A was used to stimulate proliferation
and anti-IgG was used as a negative antibody control
(Additional file 1: Figure S1b). CellSearch runs were car-
ried out at three different exposure (0.4 s, 0.6 s, 0.8 s) with
no difference evident, thus 0.8 s was chosen as standard
for analysis (data not shown). Experiments were repeated
in duplicate.
Statistics
The association of CTC number with clinical characteris-
tics and patient demographics were assessed using Fisher’s
exact test for dichotomous factors, and Mann-Whitney
tests for continuous data. The Kaplan-Meier method was
used to estimate overall survival, and the differencebetween CTC cohorts compared using the log-rank test.
Chi-square tests were used to analyse categorical data.
Data cutoff for survival estimates was March 1st, 2015:
outcomes were censored if a patient had not died before
this date. Overall survival is defined as the time from first
CTC sample until death from any cause, cancer-related or
otherwise. Statistics were analysed using GraphPad Prism
6.03 for Windows. All p values were two sided and consid-
ered statistically significant at <0.05.
Results
Patient characteristics
As only one free channel position for either Ki67 or
vimentin antibodies was available using CellSearch, analyses
were conducted in separate patient cohorts: a ‘vimen-
tin cohort’ and a ‘Ki67 cohort’. Patient details from
each are recorded in Tables 1 and 2. From the vimen-
tin cohort, 93 patients in total were recruited: 63
patients were vimentin CTC-negative (no vimentin-
positive CTCs) at baseline and 30 patients were
vimentin CTC-positive (≥1 vimentin-positive CTC)
(Tables 1 and 3, Fig. 1a). Both vimentin patient co-
horts had similar baseline characteristics, other than
an increase in visceral/multiple metastatic sites for
patients in the vimentin CTC-positive group (43.3 vs
30.2 %) which was consistent with more patients in
this group reported to be receiving at least a 3rd line
of systemic treatment (40 vs 22.2 %) (Table 1). The
majority across both groups were post-docetaxel and
due to receive at least 2nd line systemic treatment
(Table 1).
From the Ki67 cohort, 51 patients in total were
recruited: 28 patients were Ki67 CTC-negative (no Ki67-
positive CTCs) and 23 patients were Ki67 CTC-positive
at baseline (≥1 Ki67-positive CTCs) (Tables 2 and 3,
Fig. 1b). The majority of patients across the cohort were
beyond 1st line systemic treatment. For the Ki67 CTC-
positive group, increases in patients with ≥3 metastatic
sites (30.4 vs 14.3 %) and visceral metastatic sites (43.5
vs 21.4 %) were again consistent with more patients in
this group reported to be receiving at least a 3rd line of
systemic treatment (30.4 vs 10.7 %) (Table 2).
CTC characteristics
Table 3 provides a summary of CTC characteristics at
baseline within the 2 cohorts. Vimentin expression was
analysed in 142 samples from 93 patients: all patients
were sampled at baseline, 49 of whom were also sampled
at later timepoints during the same treatment regimen.
80/93 (86 %) of baseline samples from patients were
CTC-positive overall, and 30/93 (32.3 %) vimentin CTC-
positive. 69/93 (74.2 %) patients belonged to the previ-
ously described ‘unfavourable’ prognostic category (≥5
standard CTCs) for overall CTC count, while 10/93
Table 1 Baseline characteristics of patients with prostate cancer













Number of metastasic sites
1 26/63 (41.3) 11/30 (36.7)
2 21/63 (33.3) 9/30 (30)
3+ 15/63 (23.8) 10/30 (33.3)
Not stated 1/63 (1.6) 0/30 (0)
Metastasic sites
Lymph Nodes alone 3/63 (4.8) 1/30 (3.3)
Bone alone 24/63 (38.1) 10/30 (33.3)
Bone and lymph nodes 17/63 (27) 6/30 (20)
Visceral/multiple sites 19/63 (30.2) 13/30 (43.3)
Treatment at time of 1st CTC specimen
Cabazitaxel 7/63 (11.1) 7/30 (23.3)
Docetaxel 7/63 (11.1) 3/30 (10)
Abiraterone 26/63 (41.3) 11/30 (36.7)
Enzalutamide 5/63 (7.9) 2/30 (6.7)
Radium 223 2/63 (3.2) 2/30 (6.7)
Others/Not Stated 16/63 (25.4) 5/30 (16.7)
Line of treatment at time of 1st CTC specimen
1 10/63 (15.9) 4/30 (13.3)
2 17/63 (27) 8/30 (26.7)
3+ 14/63 (22.2) 12/30 (40)
Not stated 22/63 (34.9) 6/30 (20)
Previous treatments
Primary surgery 10/63 (15.9) 7/30 (23.3)
Primary radiotherapy 27/63 (42.9) 12/30 (40)
Docetaxel 42/63 (66.7) 23/30 (76.7)
Enzalutamide 2/63 (3.2) 4/30 (13.3)
Cabazitaxel 10/63 (15.9) 7/30 (23.3)
Abiraterone 21/63 (33.3) 12/30 (40)
Total CTC levels at baseline
Mean 98.8 492.6
Range 0–1185 1–4310
Table 2 Baseline characteristics of patients with prostate cancer
according to Ki67 CTC status
Characteristic Ki67 CTC-negative
patients (no Ki67
+ ve CTCs) (%)
Ki67 CTC-positive
patients (≥1 Ki67
+ ve CTC) (%)




Number of metastasic sites
1 12/28 (42.9) 8/23 (34.8)
2 10/28 (35.7) 8/23 (34.8)
3+ 4/28 (14.3) 7/23 (30.4)
Not stated 2/28 (7.1) 0/23 (0)
Metastasic sites
Lymph Nodes alone 0/28 (0) 0/23 (0)
Bone alone 12/28 (42.9) 8/23 (34.8)
Bone and lymph nodes 8/28 (28.6) 5/23 (21.7)
Visceral/multiple sites 6/28 (21.4) 10/23 (43.5)
Unknown/Not stated 2/28 (7.1) 0/23 (0)
Treatment at time of 1st CTC specimen
Cabazitaxel 0/28 (0) 6/23 (23.1)
Docetaxel 6/28 (21.4) 3/23 (13)
Abiraterone 13/28 (46.4) 11/23 (47.8)
Others/Not stated 9/28 (32.1) 3/23 (13)
Line of treatment at time of 1st CTC specimen
1 5/28 (17.9) 3/23 (13)
2 8/28 (28.6) 5/23 (21.7)
3+ 3/28 (10.7) 7/23 (30.4)
Not stated 12/28 (42.9) 8/23 (34.8)
Previous treatments
Primary surgery 5/28 (17.9) 3/23 (13)
Primary radiotherapy 6/28 (21.4) 5/23 (21.7)
Docetaxel 21/28 (75) 20/23 (87)
Enzalutamide 1/28 (3.6) 0/23 (0)
Cabazitaxel 1/28 (3.6) 0/23 (0)
Abiraterone 2/28 (7.1) 5/23 (21.7)
Total CTC levels at baseline
Mean 12.9 92.8
Range 0–79 2–316
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CTCs [4]. In the unfavourable prognostic category,
vimentin-positive CTC prevalence was higher (28/69
samples, 40.6 %). Only 1/93 patients (1.1 %) had samples
containing vimentin-positive CTCs exclusively, with theother 29/30 vimentin-positive CTC samples harbouring
at least one vimentin-negative CTC. 960/26299 (3.7 %)
of CTCs were vimentin-positive across baseline samples
from the cohort.
For Ki67 expression, 90 samples from 51 patients were
analysed: all patients were sampled at baseline, 39 of
whom were also sampled at later timepoints during the
Table 3 Baseline CTC characteristics of patients with prostate
cancer according to vimentin and Ki67 CTC status
Vimentin cohort
Number of pts with ≥1 CTC (%)
Total CTC 80/93 (86)
Vimentin CTC 30/93 (32.3)
Number of pts with ≥5 CTC (%)
Total CTC 69/93 (74.2)
Vimentin CTC 10/93 (10.8)
Number of pts with ≥5 CTC and ≥1 vimentin CTC 28/69 (40.6)
Number of pts with only Vimentin-positive CTC 1/93 (1.1)
Number of Vimentin-positive CTCs in total 960/26299 (3.7)
Ki67 cohort
Number of pts with ≥1 CTC (%)
Total CTC 41/51 (80.4)
Ki67 CTC 23/51 (45.1)
Number of pts with ≥5 CTC (%)
Total CTC 35/51 (68.6)
Ki67 CTC 12/51 (23.5)
Number of pts with ≥5 CTC and ≥1 Ki67 CTC 22/35 (62.9)
Number of pts with only Ki67-positive CTC 3/51 (5.9)
Number of Ki67-positive CTCs in total 307/2495 (12.3)
a
Fig. 1 Vimentin- and Ki67-expressing CTCs from castrate-resistant prostate ca
staining (a) and Ki67 staining (b) in CTCs from three patients in each analysis.
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ples from patients were CTC-positive overall, and 23/51
(45.1 %) Ki67 CTC-positive. 35/51 (68.6 %) patients
belonged to the ‘unfavourable’ prognostic category (≥5
standard CTCs) for overall CTC count, while 12/51
(23.5 %) patients had samples with ≥5 Ki67-positive
CTCs. In the unfavourable prognostic category, Ki67-
positive CTC prevalence was higher (22/35 samples,
62.9 %). 3/51 patients (5.9 %) had samples containing
Ki67-positive CTCs exclusively, with the other 20/23
Ki67-positive CTC samples harbouring at least one
Ki67-negative CTC. 307/2495 (12.3 %) of CTCs were
Ki67-positive across first samples from the cohort.
Prognostic impact of vimentin/Ki67 CTC expression
We first sought to ensure that, in line with that previously
described, a prognostic difference was evident across both
cohorts between those patients in the unfavourable CTC-
positive prognostic category (≥5 standard CTCs per
7.5 ml) and those in the favourable CTC-positive prognos-
tic category (<5 standard CTCs per 7.5 ml) at baseline
sampling.
Across the vimentin and Ki67 cohort, baseline PSA
was significantly higher in those patients who had
unfavourable prognosis at baseline compared to those
who were in the favourable category (mean PSA 671.2 vs
278.3, p = <0.0001) (Additional file 1: Figure S2a). A
significant difference in median OS was also evident in pa-
tients who were in the unfavourable category at baseline
compared to those in the favourable group (375 vs 712 days,b
ncer patients Representative pictures from CellSearch system of vimentin
Pt=patient, vim=vimentin
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(Additional file 1: Figure S2b). We thus validated that the
prognostic value of standard CTCs in our two cohorts was
consistent with what has been reported previously [4, 5].
We next asked whether the baseline presence of
vimentin- or Ki67-expression in CTC could have prognos-
tic implications. Baseline PSA was not significantly differ-
ent in those patients who were CTC-vimentin positive at
baseline compared to those who had no vimentin-positive
CTCs (mean PSA 537.0 vs 463.2, respectively; p = 0.33)
(Fig. 2a). However a statistically significant difference in
OS was evident between patients with vimentin-positiveFig. 2 Prognostic impact of vimentin- and Ki67-expressing CTC. a-b Progno
compared to those with no vimentin-expressing CTC, as assessed by bar ch
survival (b). c-d Prognostic comparison of patients with Ki67-expressing CT
assessed by bar charts comparing baseline PSA (c), and Kaplan-Meier plots
log-rank tests for (b) and (d); Bar charts show mean +/- standard deviationCTC and those with no vimentin-positive CTC (median
305 days vs 453 days, respectively; HR 1.8, 95 % CI 1.09–
3.83, p = 0.0293) (Fig. 2b). When sub-divided into patients
belonging to the unfavourable prognostic category of ≥5
standard CTCs overall, the presence of 1 vimentin-
positive CTC did not diminish survival further
(median 283 days vs 283 days, HR 1.33, 95 % CI
0.72–2.57, p = 0.347), and there was also no survival
difference evident when the patients with the highest
proportion of vimentin-positive CTCs were compared to
those with the highest proportion of vimentin-negative
CTCs (median 358 days vs 174 days, respectively; HRstic comparison of patients with vimentin-expressing CTC at baseline
arts comparing baseline PSA (a), and Kaplan-Meier plots of overall
C at baseline compared to those with no Ki67- expressing CTC, as
of overall survival (d). Mann-Whitney tests performed for (a) and (c),
, p=<0.05
Lindsay et al. BMC Cancer  (2016) 16:168 Page 7 of 111.36, 95 % CI 0.47–4.13, p = 0.569) (Additional file 1:
Figure S3a, b).
In the Ki67 cohort, baseline PSA was not significantly
different in those patients who were CTC Ki67-positive
at baseline compared to those who had no CTC Ki67-
positive CTC (mean PSA 695.7 vs 697.6, respectively;
p = 0.228) (Fig. 2c). A statistically significant difference
in OS was evident between patients with Ki67-
positive CTC and those with no Ki67-positive CTC
(median 512 days vs 751 days, respectively; HR 2.37,
95 % CI 1.35–5.23, p = 0.0091), although it was not
clear that the presence of 1 Ki67-positive CTC dimin-
ished survival further when patients were sub-divided
into the unfavourable prognostic category of ≥5
standard CTCs overall (median 537 days vs 725 days,
HR 2.02, 95 % CI 0.89–4.24, p = 0.099) (Fig. 2d and
Additional file 1: Figure S3c). There was also no
survival difference evident when the patients with the
highest proportion of Ki67-positive CTCs were
compared to those with the highest proportion of
Ki67-negative CTCs (median 600 days vs 664 days,
respectively; HR 1.29, 95 % CI 0.52–3.33, p = 0.581)
(Additional file 1: Figure S3d). Overall, this suggested
that the presence of vimentin-positive or Ki67-
positive CTC is more clinically important than their
relative numbers or proportions, and that their pres-
ence in the early stages of advanced disease could be
of greater prognostic significance than in later stages.Predictive impact of vimentin/Ki67 CTC expression
As vimentin expression has been associated with stem
cell properties and treatment resistance in CTCs, we
hypothesized that the mesenchymal profile of CTCs may
become more apparent during treatment, even if overall
CTC numbers were to diminish. We also questioned if
the proliferative capacity of CTC, as represented by Ki67
expression, would be diminished by treatment, particu-
larly those treatments with anti-proliferative properties
such as docetaxel and cabazitaxel.
We first tested whether the proportion of patients with
vimentin-expressing CTC had altered between baseline
CTC samples and paired follow-up CTC samples taken
at cycles 2–3. When using ≥1 vimentin-positive CTC as
a cutoff, there was no difference in patient proportion
observed: 30/93 patients harboured vimentin-expressing
CTC before treatment, compared to 19/49 patients after
treatment (32.3 vs 38.8 %, p = 0.437) (Table 4). There was
also no difference evident using ≥5 vimentin-positive CTC
as a cutoff (10/93 patients vs 7/49 patients, 10.8 vs 14.3 %,
p = 0.558) (Table 4). We next asked if the proportion of
vimentin-expressing CTC may change with treatment in
vimentin-positive CTC patients: ratio of total CTC/vimen-
tin-positive CTC was not significantly different before andafter treatment (mean 51 at baseline vs 46.2 after treat-
ment; p = 0.298) (Fig. 3a).
For Ki67 CTC testing, no difference in patient propor-
tion harbouring Ki67-positive CTC was observed before
and after treatment, regardless of whether ≥1 Ki67-
positive CTC or ≥5 Ki67-positive CTC was used as a
cutoff (≥1 CTC: 23/51 patients before vs 15/39 patients
after, 45.1 vs 38.5 %, p = 0.528; ≥5 CTC: 12/51 patients
before vs 6/39 patients after, 23.5 vs 15.4 %, p = 0.336)
(Table 4). The proportion of Ki67-expressing CTCs rela-
tive to Ki67-negative CTC did not significantly change
(mean 24.1 at baseline vs 19.3 after treatment; p = 0.85)
(Fig. 3b). Thus, overall there was no significant change
in proportions of Ki67/vimentin patients or CTCs be-
tween baseline and post-treatment samples.
Discussion
Here we report CTC expression of vimentin and Ki67 in
advanced/metastatic prostate cancer, offering a clinical
insight into their mesenchymal and proliferative proper-
ties. We have established a method for testing CTC ex-
pression of Ki67 and vimentin in the normal pathway of
prostate cancer care. In line with previous studies, we
confirmed the prognostic value of detection of ≥5 stand-
ard CTCs at baseline through analysis of PSA and OS.
No significant difference was evident when baseline PSA
was split into vimentin-positive and Ki67-positive CTC
cohorts, but there was a significantly reduced OS in the
vimentin-positive and Ki67-positive CTC cohorts com-
pared to those patients with no vimentin/Ki67-positive
CTCs, respectively. In both Ki67 and vimentin cohorts, no
additional prognostic significance of Ki67- or vimentin-
positive CTCs was evident when cohorts were subdivided
into the unfavourable prognostic category of ≥5 standard
CTCs overall, or when patients with high proportions of
Ki67/vimentin-positive CTCs were compared to patients
with high proportions of Ki67/vimentin-negative CTCs.
This suggests that the presence of vimentin-positive or
Ki67-positive CTC is more clinically important than their
relative numbers or proportions, and that their presence
in the early stages of advanced disease could be of greater
prognostic significance than in later stages. Finally,
there was no change in patient percentage or CTC
proportion with Ki67- or vimentin-expressing CTCs
before and after treatment, suggesting the potential of
these techniques to offer predictive benefits of treat-
ment remains unestablished.
It is important to reflect on the deficiencies of this
dataset and its analysis. The results here are hypothesis-
generating and should be interpreted within the context
of a retrospective observational design. Survival data
reported was not adjusted for patient treatment, and
mCRPC patient numbers tested were relatively small,
particularly for the Ki67 cohort. The variability of
Table 4 Change in patient Ki67 and vimentin CTC profile with treatment. Chi-squared test to analyse CTC frequencies in treatment
groups. Samples from the second column were taken at cycles 2–3 following initiation of treatment
Baseline sample before treatment (%) First sample after treatment start (%)
Number of patients with Ki67 + ve CTC (%) 23/51 (45.1) 15/39 (38.5) p = 0.528
Number of patients with ≥5 Ki67 + ve CTC (%) 12/51 (23.5) 6/39 (15.4) p = 0.336
Number of patients with Vim + ve CTC (%) 30/93 (32.3) 19/49 (38.8) p = 0.437
Number of patients with ≥5 Vim + ve CTC (%) 10/93 (10.8) 7/49 (14.3) p = 0.558
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vival was not evaluated in our study: with small patient
numbers, an imbalance of treatment line and therapy
was inevitable between our patient cohorts and would
have confounded such an analysis. Finally, an initial bio-
logical selection during CellSearch should also be noted:
it will only test for Ki67 and vimentin after patient CTC
have been initially isolated using EPCAM-coated ferro-
magnetic beads, an epithelial-antibody based selection.
This process is consistent across all patient cohorts ana-
lysed, but a fully representative picture of mesenchymal
and proliferative CTCs may be impaired as a conse-
quence. As an alternative to antibody-based CTC selec-
tion via CellSearch, a number of other CTC detection
techniques are in different stages of development, some
with the aim of isolating CTC by their large size rather
than their biological phenotype: a similar analysis of
CTC vimentin expression in mCRPC using these tech-
niques would be of future interest, and could offer a
more accurate picture of its clinical relevance.
We noted a significant reduction of OS in the patient
cohort harbouring vimentin-expressing CTC: HR wasFig. 3 Change in vimentin- and Ki67-expressing CTC after initiation of treatm
compared to total CTC expression, at baseline and after treatment start b) Bar
to total CTC expression, at baseline and after treatment start. ‘Post-treatment’
Mann-Whitney test; Bar charts show mean +/- standard deviation, p=<0.051.8, with a median of 305 days OS in the vimentin-
positive CTC population compared to 453 days for those
patients with no vimentin-positive CTCs. Given some of
the study limitations noted in the previous paragraph
(ie the possibility that a high percentage of mesenchymal
CTC are missed by the CellSearch technology), this find-
ing merits further examination and has future potential to
offer important insight regarding mesenchymal CTC and
their treatment. It is possible that this difference could
have been more profound using CTC enrichment
platforms that are not antibody-based. More opportunity
to perform detailed study of vimentin co-localisation with
other CTC markers should hopefully arise soon, given the
recent identification and clinical characterisation of a non-
commercial cell surface vimentin antibody that detects
CTCs from epithelial cancers with high sensitivity and
specificity [28].
Mesenchymal or EMT CTC, as represented by vimentin
expression in this study, have previously been associated
with tumour invasiveness, chemoresistance, CTC cluster-
ing, stem cell characteristics, and poorer clinical outcomes
[29, 30]. Although not validated by our study, the resultsent a) Bar chart assessing proportion of vimentin-positive CTC expression,
chart assessing proportion of Ki67-positive CTC expression, compared
samples were taken at cycles 2-3 following initiation of treatment.
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biological and clinical phenotype. In parallel with the
poorer prognosis seen in this study for those patients with
vimentin-positive CTCs at baseline, the lack of survival
difference observed in those patients whose samples con-
tained the highest proportion of vimentin-positive CTCs
is consistent with (but does not confirm) the stem cell the-
ory that just one vimentin-positive cell will suffice to con-
tribute to poorer outcomes. Armstrong and colleagues
previously used the CellSearch platform to offer a detailed
biological examination of vimentin and other markers of
the EMT program in samples from patients with breast
and prostate cancer, revealing the existence and high
frequency of CTCs that can co-express epithelial and mes-
enchymal proteins [25]. Using a cutoff of 1 vimentin-
positive CTC, 30/93 CRPC patients from our study had
baseline samples with CTCs that co-expressed cytokeratin
with vimentin, compared to 10/10 CRPC patients
documented previously. This disparity could be
accounted for by differences between patient charac-
teristics and staining methods employed in the two
studies, but here we have also been able to build on
the clinical aspect of vimentin analysis by offering the
larger clinical cohort with longer-term follow-up that
was recommended in the previous study.
A significant reduction of OS was also observed in the
patient cohort harbouring Ki67-expressing CTC: HR was
2.37, with a median of 512 days OS in the Ki67-positive
CTC population compared to 751 days for those patients
with no Ki67-positive CTCs. One previous study has ex-
plored the biological character of Ki67-positive CTC using
an alternative CTC isolation platform, also offering some
preliminary insight from CTC enumeration of 10 patient
samples: 12.3 % of CTCs were Ki67-positive in our study,
compared to 7–73 % from 4 CRPC patients reported previ-
ously [18]. We have thus been able to consolidate the
results of this initial study using larger patient numbers
and the CellSearch platform, suggesting again that there is
potential prognostic clinical insight to be gained by exam-
ining proliferative and non-proliferative CTC subpopula-
tions. Future studies can now focus prospectively on
prognostic validation of Ki67-positive CTCs and their
response to particular treatment types.
A number of other prostate cancer CTC studies have
recently elaborated on the original work which showed
the prognostic value of CTC in mCRPC [4, 5]. In terms
of CTC enumeration, a putative predictive role for
‘categorical’ CTC enumeration (ie whether a patient is
CTC positive or not) has been suggested after 1 cycle of
chemotherapy, an evaluation that can be performed weeks
ahead of standard response approaches such as PSA and
CT [31]. A recent large prospective study suggested that
CTC count and LDH value could be a surrogate of overall
survival in mCRPC treated with abiraterone [6]. On theother end of the research spectrum, the biological hetero-
geneity of prostate cancer with treatment has also recently
been re-illustrated despite its seemingly predictable clinical
pattern of metastatic spread compared to many other
cancers: CTC measurement and next generation single cell
sequencing of metastatic prostate cancer patient revealed a
vast complexity of clonal evolution, a finding consistent
with the metastasis-to-metastasis spread of multiple
tumour clones recently revealed by prostate tumour
biopsies [32–34]. Many of these studies have concentrated
on androgen receptor expression and its predictive cap-
acity [11, 12, 35]. Overall, the vast range of CTC enumer-
ation, genomic and biological progress achieved in these
studies offer an encouraging window of insight towards the
future for circulating biomarkers in prostate cancer.
Conclusions
Here we show that routine clinical testing of vimentin and
Ki67 expression in CTC derived from mCRPC patients is
feasible. A significant reduction in OS for patients with
baseline CTC vimentin and Ki67 expression suggests that
largescale prospective analyses would be important to fur-
ther explore these potential links. Future studies will also
require further detailed correlation of vimentin/Ki67 CTC
expression and response to certain treatment types: for ex-
ample, the predictive capacity of lost or increased Ki67
CTC-expression in a large cohort of mCRPC patients
treated exclusively with anti-proliferative chemotherapy
agents such as docetaxel or cabazitaxel. Finally, a number
of alternative CTC-isolation techniques have been devel-
oped and merit further analysis for such clinical correl-
ation studies: size-based filtration techniques may be
particularly helpful for vimentin-expressing CTC which
may not be efficiently captured by techniques based on
epithelial-antibody expression.
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